Cancer Synoptic Reporting Project Group
24 January 2022 at 17:30 UTC
Meeting Recording (GoogleDrive)
Discussion items
| Item | Description | Owner | Notes | Action |
|---|---|---|---|---|
| 1 | IHC |
| a. her2 in breast tissue
b. her2 in breast cancer from lymph node
c. her2 in breast cancer from any tissue site specimen
Conclusion to this good discussion is that there exists a need to develop a mechanism to note an observation made that is a proxy statement - specifically, an observation about a primary neoplasm location made on a metastatic specimen. Alternatively, be less specific in these observations and rely more upon the info model. | |
| 2 | Treatment effect | Continue discussion: What are we measuring when assessing "treatment effect"? Is this a histologic change? Viability of tumor cells?
| Briefly discussed, but general comments confer that this is a histologic feature property of measure. Will address and confirm at next work group meeting Did not discuss | |
| 3 | Lymph nodes |
2. Management of observables for lymph node involvement. Example: | Great discussion. Assume site specific where clinically called for...use reference materials if provided.Did not discuss | |
| 4 | AJCC update? | Any updates that can be shared? | Jim Case meeting with AJCC on Wednesday 26-Jan to continue/finalize contract issues |
Meeting Files
| Attachments |
|---|
Previous Meetings
| Content Report Table | ||||||||
|---|---|---|---|---|---|---|---|---|
|